Visiox Pharma acquires licensing rights for Omlonti in US
Click Here to Manage Email Alerts
Key takeaways:
- Visiox Pharma licenses Omlonti from Santen Pharmaceutical.
- Omlonti is indicated to reduce IOP in patients with open-angle glaucoma or ocular hypertension.
Visiox Pharma has entered into a definitive agreement with Santen Pharmaceutical to license product manufacturing and commercialization rights for Omlonti in the U.S., according to a press release.
Santen will receive an equity stake in Visiox upfront and will be eligible to receive sales milestone payments and royalties on net sales of Omlonti (omidenepag isopropyl ophthalmic solution) 0.002% in the U.S.
Image: Adobe Stock
The prostaglandin E2 receptor agonist was approved by the FDA in 2022 to reduce elevated IOP in the treatment of open-angle glaucoma or ocular hypertension.
Visiox plans to launch Omlonti in 2024.
“We are pleased to add Omlonti to our innovative pharmaceutical portfolio,” Ryan Bleeks, CEO of Visiox, said in the release. “We believe this is a compelling transaction, as it expands our addressable market opportunity enhancing our long-term growth and profitability.”
Read more about
Click Here to Manage Email Alerts